Comparison of Homologous Recombination Repair Gene Next-Generation Sequencing Analysis in Patients With Metastatic Castration-Resistant Prostate Cancer Between Local and Central Laboratories in Korea
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background: Following success of the phase III PROfound trial, the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib was approved by the US Food and Drug Administration in May 2020 for adult patients with deleterious homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC). As locally adopted multigene panel next-generation sequencing (NGS) assays for selecting PARP inhibitor candidates have not been thoroughly evaluated, we compared the analytical performance of the FoundationOne CDx (Foundation Medicine, Inc., Cambridge, MA, USA) (central laboratory) and other NGS assays (local laboratory) with samples from the PROfound trial in Korea. Methods: One hundred PROfound samples (60 HRR mutation [HRRm] cases and 40 non-HRRm cases) were analyzed. The results of HRR gene mutation analysis were compared between the FoundationOne CDx and two other NGS assays [SureSelect Custom Design assay (Agilent Technologies, Inc., Santa Clara, CA, USA) and Oncomine Comprehensive assay (Thermo Fisher Scientific, Inc., Waltham, MA, USA)]. Results: The positive percent agreement for single nucleotide variants (SNVs) and insertion/deletions (indels) between the central laboratory and local laboratory was 98.7%–100.0%. The negative percent agreement and overall percent agreement (OPA) for SNVs and indels between central and local laboratories were both 100%. Compared with that of the FoundationOne CDx assay, the OPA for copy number variations of the Oncomine Comprehensive and SureSelect Custom assays reached 99.8%–100%. Most mCRPC patients harboring a deleterious genetic variant were successfully identified with both local laboratory assays. Conclusions: The NGS approach at a local laboratory showed comparable analytical performance for identifying HRRm status to the FoundationOne CDx assay used at the central laboratory.
Abstract
Background: Following success of the phase III PROfound trial, the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib was approved by the US Food and Drug Administration in May 2020 for adult patients with deleterious homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC). As locally adopted multigene panel next-generation sequencing (NGS) assays for selecting PARP inhibitor candidates have not been thoroughly evaluated, we compared the analytical performance of the FoundationOne CDx (Foundation Medicine, Inc., Cambridge, MA, USA) (central laboratory) and other NGS assays (local laboratory) with samples from the PROfound trial in Korea. Methods: One hundred PROfound samples (60 HRR mutation [HRRm] cases and 40 non-HRRm cases) were analyzed. The results of HRR gene mutation analysis were compared between the FoundationOne CDx and two other NGS assays [SureSelect Custom Design assay (Agilent Technologies, Inc., Santa Clara, CA, USA) and Oncomine Comprehensive assay (Thermo Fisher Scientific, Inc., Waltham, MA, USA)]. Results: The positive percent agreement for single nucleotide variants (SNVs) and insertion/deletions (indels) between the central laboratory and local laboratory was 98.7%–100.0%. The negative percent agreement and overall percent agreement (OPA) for SNVs and indels between central and local laboratories were both 100%. Compared with that of the FoundationOne CDx assay, the OPA for copy number variations of the Oncomine Comprehensive and SureSelect Custom assays reached 99.8%–100%. Most mCRPC patients harboring a deleterious genetic variant were successfully identified with both local laboratory assays. Conclusions: The NGS approach at a local laboratory showed comparable analytical performance for identifying HRRm status to the FoundationOne CDx assay used at the central laboratory.
참고문헌 (16)
- Adashek JJ, "Clinical development of PARP inhibitors in treating metastatic castration-resistant prostate cancer", Cells, 8, pp.860~ (2019)
- Murai J, "Trapping of PARP1 and PARP2 by clinical PARP inhibitors", Cancer Res, 72, pp.5588~5599 (2012)
- Ryan CJ, "TRITON3: an international, randomized, open-label, phase III study of the PARP inhibitor rucaparib vs. physician’s choice of therapy for patients with metastatic castration-resistant prostate cancer (mCRPC) associated with homologous recombination deficiency (HRD)", J Clin Oncol, 36, pp.TPS389~ (2018)
- Sigorski D, "Poly(ADP-ribose) polymerase inhibitors in prostate cancer: molecular mechanisms, and preclinical and clinical data", Target Oncol, 15, pp.709~722 (2020)
- Pritchard CC, "Inherited DNA-repair gene mutations in men with metastatic prostate cancer", N Engl J Med, 375, pp.443~453 (2016)
- Cancer Genome Atlas Research Network, "The molecular taxonomy of primary prostate cancer", Cell, 163, pp.1011~1025 (2015)
- de Bono J, "Olaparib for metastatic castration-resistant prostate cancer", N Engl J Med, 382, pp.2091~2102 (2020)
- Garje R, "PARP inhibitors in prostate and urothelial cancers", Front Oncol, 10, pp.114~ (2020)
- Plagnol V, "A robust model for read count data in exome sequencing experiments and implications for copy number variant calling", Bioinformatics, 28, pp.2747~2754 (2012)
- Tatsi C, "Large genomic aberrations in corticotropinomas are associated with greater aggressiveness", J Clin Endocrinol Metab, 104, pp.1792~1801 (2019)
- CLSI, "User protocol for evaluation of qualitative test performance. 2nd ed. CLSI EP12-A2", Clinical and Laboratory Standards Institute, ~ (2008)
- Khodakov D, "Diagnostics based on nucleic acid sequence variant profiling: PCR, hybridization, and NGS approaches", Adv Drug Deliv Rev, 105, pp.3~19 (2016)
- 성문우, "Three-Year Experience of an External Proficieny Testing Survey for Next-Generation Sequencing-Based Testing for Germline Mutation", Laboratory Medicine and Quality Assurance, 42(1), pp.48~53 (2020), 대한진단검사정도관리협회[DOI]
- Zakrzewski F, "Targeted capture-based NGS is superior to multiplex PCR-based NGS for hereditary BRCA1 and BRCA2 gene analysis in FFPE tumor samples", BMC Cancer, 19, pp.396~ (2019)
- Castro E, "Targeting DNA repair : the role of PARP inhibition in the treatment of castration-resistant prostate cancer", Cancer J, 22, pp.353~356 (2016)
- Heeke AL, "Prevalence of homologous recombination-related gene mutations across multiple cancer types", JCO Precis Oncol, 2018 (2018)